Our top pick for
Building a portfolio

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Immatics N.V is a biotechnology business based in the US. Immatics N-V shares (IMTX) are listed on the NASDAQ and all prices are listed in US Dollars. Immatics N-V employs 227 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Building a portfolio
Our top pick for
Beginners
Our top pick for
Active traders
52-week range | $8.67 - $17.25 |
---|---|
50-day moving average | $11.83 |
200-day moving average | $11.01 |
Wall St. target price | $24.01 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | $-0.08 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Revenue TTM | $31.3 million |
---|---|
Gross profit TTM | $-35,832,000 |
Return on assets TTM | -22.41% |
Return on equity TTM | -724.1% |
Profit margin | 0% |
Book value | N/A |
Market capitalisation | $758 million |
TTM: trailing 12 months
There are currently 1.9 million Immatics N-V shares held short by investors – that's known as Immatics N-V's "short interest". This figure is 98.4% up from 944,925 last month.
There are a few different ways that this level of interest in shorting Immatics N-V shares can be evaluated.
Immatics N-V's "short interest ratio" (SIR) is the quantity of Immatics N-V shares currently shorted divided by the average quantity of Immatics N-V shares traded daily (recently around 2.0 million). Immatics N-V's SIR currently stands at 0.96. In other words for every 100,000 Immatics N-V shares traded daily on the market, roughly 960 shares are currently held short.
However Immatics N-V's short interest can also be evaluated against the total number of Immatics N-V shares, or, against the total number of tradable Immatics N-V shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Immatics N-V's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Immatics N-V shares in existence, roughly 30 shares are currently held short) or 0.041% of the tradable shares (for every 100,000 tradable Immatics N-V shares, roughly 41 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Immatics N-V.
Find out more about how you can short Immatics N-V stock.
We're not expecting Immatics N-V to pay a dividend over the next 12 months.
Immatics N. V. , a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct therapeutic modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its ACTengine product candidates are in Phase I clinical trials, which include IMA201 that targets melanoma-associated antigen 4 or 8 in patients with solid tumors; IMA202 that targets melanoma-associated antigen 1 in patients with various solid tumors, including squamous non-small cell lung carcinoma and hepatocellular carcinoma; and IMA203 that targets preferentially expressed antigen in melanoma in adult patients with relapsed and/or refractory solid tumors, as well as IMA204, an anti-tumor therapy, which is in preclinical studies that targets tumor stroma cell. The company's TCR Bispecifics product candidates, which are in preclinical studies includes IMA401, a cancer testis antigen for the treatment of solid tumor; and IMA402 for the treatment of solid tumors. It also develops IMA101, a multi-target precision immunotherapy; and IMA301, an allogenic cellular therapy product candidate.
Features, fees and complaints to consider before you apply for a T. Rowe Price account.
Steps to owning and managing ZTO, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZOM, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZI, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZKIN, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZION, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZNTL, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZGYH, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZEAL, with 24-hour and historical pricing before you buy.
Steps to owning and managing CTIB, with 24-hour and historical pricing before you buy.